Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.

Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates. Clin Cases Miner Bone Metab. 2014 May;11(2):126-8 Authors: Sprini D, Di Stefano L, Rini GB, Cianferotti L, Napoli N Abstract Treatment with bisphosphonates induces differentiation and activation of Vγ9Vδ2 T lymphocytes obtained from peripheral blood showing also an antitumoral effect in both in vitro and in vivo models. Aim of the present study was to determine in vivo the effect of BPs treatment in patients affected with osteoporosis on Vγ9Vδ2 T lymphocytes. We have studied Vγ9Vδ2 T lymphocytes expansion and differentiation from PBMC obtained from osteoporotic patients treated with one of the following bisphosphonates zoledronate, alendronate, neridronate or risedronate. We have found that zoledronic acid, followed by alendronate was the most effective on reducing CM population (100%) and increasing TEM and TEMRA γδ population. Our results indicate that in vivo treatment with BPs induces Vγ9Vδ2 cells to mature toward the effector phenotype, which may induce more antiresorptive responses. PMID: 25285142 [PubMed]
Source: Clinical Cases in Mineral and Bone Metabolism - Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research